caffeine has been researched along with Alcoholic Cirrhosis in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the polygenic regulated caffeine metabolism in a group of 226 patients with liver alcoholic cirrhosis classified according to the Child score." | 3.70 | Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients. ( Bechtel, PR; Bechtel, YC; Brientini, MP; Haffen, E; Lelouët, H; Miguet, JP; Paintaud, G, 2000) |
| "Levetiracetam is an antiepileptic drug approved for use as adjunctive therapy in adults with partial-onset seizures." | 2.71 | Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. ( Brockmöller, J; Coupez, R; Lochs, H; Roots, I; Thomsen, T; Wittstock, M, 2005) |
| "Caffeine has a preventive effect on ALF." | 1.42 | Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells. ( Dai, X; Li, J; Lv, X; Wang, H; Wang, Q; Yang, F; Yang, W; Yang, Y; Zhao, H, 2015) |
| " A comparison between the single and the "cocktail" dosage did not reveal any significant differences in the pharmacokinetic parameters." | 1.28 | [Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases]. ( Henschel, L; Hoffmann, A; Huster, A; Jorke, D; Kraul, H; Reinhardt, M; Töpfer, R; Truckenbrodt, J, 1990) |
| "Caffeine (250 mg) was administered orally to 15 healthy controls and eight patients with cirrhosis." | 1.26 | Impaired elimination of caffeine in cirrhosis. ( Desmond, PV; Johnson, RF; Patwardhan, RV; Schenker, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Dai, X | 1 |
| Yang, W | 1 |
| Wang, H | 1 |
| Zhao, H | 1 |
| Yang, F | 1 |
| Yang, Y | 1 |
| Li, J | 1 |
| Lv, X | 1 |
| Brockmöller, J | 1 |
| Thomsen, T | 1 |
| Wittstock, M | 1 |
| Coupez, R | 1 |
| Lochs, H | 1 |
| Roots, I | 1 |
| Desmond, PV | 1 |
| Patwardhan, RV | 1 |
| Johnson, RF | 1 |
| Schenker, S | 1 |
| Rodopoulos, N | 1 |
| Wisén, O | 1 |
| Norman, A | 1 |
| Rector, WG | 2 |
| Everson, GT | 1 |
| Robertson, AD | 1 |
| Sharp, DS | 1 |
| Everhart, JE | 1 |
| Benowitz, NL | 1 |
| Langmann, P | 1 |
| Bienert, A | 1 |
| Zilly, M | 1 |
| Väth, T | 1 |
| Richter, E | 1 |
| Klinker, H | 1 |
| Bechtel, YC | 1 |
| Haffen, E | 1 |
| Lelouët, H | 1 |
| Brientini, MP | 1 |
| Paintaud, G | 1 |
| Miguet, JP | 1 |
| Bechtel, PR | 1 |
| Lewis, FW | 1 |
| Truckenbrodt, J | 1 |
| Kraul, H | 1 |
| Huster, A | 1 |
| Töpfer, R | 1 |
| Henschel, L | 1 |
| Hoffmann, A | 1 |
| Reinhardt, M | 1 |
| Jorke, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
1 trial available for caffeine and Alcoholic Cirrhosis
| Article | Year |
|---|---|
Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Topics: Adult; Anticonvulsants; Caffeine; Humans; Kidney Function Tests; Levetiracetam; Lidocaine; Liver Cir | 2005 |
9 other studies available for caffeine and Alcoholic Cirrhosis
| Article | Year |
|---|---|
Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells.
Topics: Actins; Alanine Transaminase; Animals; Aspartate Aminotransferases; Caffeine; Cells, Cultured; Colla | 2015 |
Impaired elimination of caffeine in cirrhosis.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Caffeine; Half-Life; Hum | 1980 |
Caffeine metabolism in patients with chronic liver disease.
Topics: Adult; Aged; Biotransformation; Caffeine; Carbon Radioisotopes; Chromatography, High Pressure Liquid | 1995 |
Sodium retention does not occur at a critical threshold of liver function in alcoholic cirrhosis.
Topics: Antipyrine; Ascites; Blood Volume; Caffeine; Cholic Acid; Cholic Acids; Humans; Liver; Liver Cirrhos | 1994 |
Coffee, alcohol, and the liver.
Topics: Alanine Transaminase; Alcohol Drinking; Animals; Caffeine; Cebus; Clinical Trials as Topic; Coffee; | 1999 |
Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis.
Topics: Bile Acids and Salts; Caffeine; Cotinine; Female; Humans; Liver Cirrhosis, Alcoholic; Male; Middle A | 2000 |
Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients.
Topics: Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Caffeine; Central Nervous System Stimu | 2000 |
Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity.
Topics: Adult; Bilirubin; Caffeine; Fasting; Female; Half-Life; Hepatic Encephalopathy; Humans; Liver; Liver | 1992 |
[Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases].
Topics: Biotransformation; Caffeine; Debrisoquin; Dipyrone; Fatty Liver, Alcoholic; Female; Hepatitis, Chron | 1990 |